The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-24

Study Completion Date

2025-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study will explore whether remote monitoring of a COPD patient can be undertaken using a wearable medical device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Inspiratory and Expiratory Pressure Training Methods in Patients With Chronic Obstructive Pulmonary Disease

NCT02326181

Chronic Obstructive Pulmonary Disease(COPD)

UNKNOWN NA

Wearable Noninvasive Positive Pressure Ventilation Device in COPD

NCT03130361

Non-Invasive Ventilation

COMPLETED NA

Feel Breathe, Restriction Device Ventilatory Nasal (COPD)

NCT01695265

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Early Warning Value of Consumer Wearable Devices in AECOPD

NCT05974670

COPD

UNKNOWN

Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance

NCT06963333

Chronic Obstructive Pulmonary Disease

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed study will assess the sensitivity of a wearable device to measure the respiratory signals in COPD patients, who have previously experienced hospitalisation due to exacerbation of their COPD. Participation in the study involves wearing a small sensor. The monitoring device will also assess the effectiveness of medication prescribed before, during, and after the COPD exacerbation to see if it has a role in directing day-to-day therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Exacerbation Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with COPD

The study population for this research consists of individuals diagnosed with COPD (Chronic Obstructive Pulmonary Disease) who have a history of exacerbation-induced hospitalization within the one-year period preceding recruitment.

Pneumowave DC

Intervention Type DEVICE

Pneumowave biosensor(s) will be used to collect data from chest +/- movement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumowave DC

Pneumowave biosensor(s) will be used to collect data from chest +/- movement.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any person aged 18 years or over.
* Current diagnosis of COPD.
* Be willing and able to comply with study procedures and be available for study visits. • Be able to use a 'smartphone or computer'.
* Be able to give written consent.
* Able to understand written and spoken English.

Exclusion Criteria

* Inability to give written informed consent.
* Known respiratory disorders are other than COPD which, in the opinion of the investigator, is the main contributor to the patient's symptoms (e.g. asthma, lung cancer, sarcoidosis, and other interstitial lung diseases (ILDs), tuberculosis, lung fibrosis, cystic fibrosis, and non-COPD related bronchiectasis).
* Known history of significant systemic and other organ-related diseases, other than COPD, which in the opinion of the investigator, is likely to interfere with the study or impact on subject safety (e.g. severe rheumatoid arthritis and Lupus, kidney, liver, endocrine, psychological disorders).
* Known to be severely alpha-1-antitrypsin deficient (PI, SZ or ZZ).
* Based on their medical record if there is any social violence/substance misuse.
* Having undergone lung surgery (e.g. lung volume reduction, lobectomy) within the last 6 months.
* Have cancer or other terminal condition which, in the opinion of the investigator, has a mortality of 12 months or less. • Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.
* Taking high-dose oral corticosteroid medication (equivalent to daily dose of ≥10 mg of prednisolone) for more than 3 consecutive months.
* Pregnancy
* Patients already involved in an ongoing research study.
* Participation in an interventional clinical study within 3 months of Visit 1 or participation in a study using an investigational medicinal product (IMP) either in the previous 3 months or in the interval from last using the IMP to 5 times its half-life.
* Patients with other significant lung disease, unable to consent, unable to use the technology (e.g. inability to use the data device, or complete the questionnaires), or at the clinician's discretion for other more significant medical/social reasons.
* Known allergy to surgical adhesive tape.
* On long-term oxygen therapy.
* Acute exacerbation of COPD within 6 weeks prior to inclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No